Research Article| Volume 41, ISSUE 2, P97-104, February 26, 2002

The effects of a soy rich diet on serum lipids: the Menfis randomized trial


      Objective: To assess beneficial effects of a soy rich diet on the main biomarkers of cardiovascular health in menopause, compared with the effects of the hormone replacement therapy (HRT). Methods: 187 healthy asymptomatic postmenopausal women, aged 39–60, were recruited and randomized into three groups: a soy rich diet group, a HRT group, and a control group. Lipid profile, body mass index, blood pressure, endometrial thickness, uterine artery resistance index (RI), were evaluated in all the participants at the baseline, after 6 months, and at the end of the study. Results: After a 6-month intervention period, the lipid profile in the soy rich diet group showed a favourable outcome, similar to that observed in the HRT group, but compliance to the diet was low. Conclusion: Soy products may be used in the prevention of cardiovascular risk in postmenopausal women because of their efficacy in contrasting the negative effects of menopause on the cardiovascular system, but our findings should be confirmed; moreover, suitable strategies to improve the compliance have to be considered.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wenger N.K.
        • Speroff L.
        • Packard B.
        Cardiovascular health and disease in women.
        N. Engl. J. Med. 1993; 329: 247-256
        • Matthews K.A.
        • Meilahn E.
        • Kuller L.H.
        • Kelsey S.F.
        • Caggiula A.W.
        • Wing R.R.
        Menopause and risk factors for coronary heart disease.
        N. Engl. J. Med. 1989; 321: 641-646
        • Jensen J.
        • Nilas L.
        • Christiansen C.
        Influence of menopause on serum lipids and lipoproteins.
        Maturitas. 1990; 12: 321-331
        • Razay G.
        • Heaton K.W.
        • Bolton C.H.
        Coronary heart disease risk factors in relation to the menopause.
        Q. J. Med. 1992; 85: 889-896
        • Stevenson J.C.
        • Crook D.
        • Godsland I.F.
        Effects of age and menopause on lipid metabolism in healthy women.
        Atherosclerosis. 1993; 98: 83-90
        • Notelovitz M.
        • Gudat J.C.
        • Ware M.D.
        • Dougherty M.C.
        Lipids and lipoproteins in women after oophorectomy and the response to oestrogen therapy.
        Br. J. Obstet. Gynaecol. 1983; 90: 171-177
        • Hjortland M.C.
        • McNamara P.M.
        • Kannel W.B.
        Some atherogenic concomitans of menopause: the Framingham study.
        Am. J. Epidemiol. 1976; 103: 304-311
        • Campos H.
        • McNamara J.R.
        • Wilson P.W.F.
        • Ordovas J.M.
        • Schaefer E.J.
        Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women.
        J. Clin. Endocrinol. Metab. 1988; 67: 30-35
      1. LaRosa JC. Women, lipoproteins and cardiovascular disease risk. Can J Cardiol 1990;(Suppl B):23B–9B.

        • Castelli W.P.
        • Garrison R.J.
        • Wilson P.W.F.
        • Abbott R.D.
        • Kalousdian S.
        • Kannel W.B.
        Incidence of coronary heart disease and lipoprotein cholesterol levels.
        JAMA. 1986; 256: 2835-2838
        • Reed D.M.
        • Strong J.P.
        • Resh J.
        • Hayashi T.
        Serum lipids and lipoproteins as predictors of atherosclerosis.
        Arteriosclerosis. 1989; 9: 560-564
        • Castelli W.P.
        The triglyceride issue: a view from Framingham.
        Am. Heart J. 1986; 112: 432-437
      2. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208.

        • Godsland I.F.
        Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000.
        Fertil. Steril. 2001; 75: 898-915
        • Stampfer M.J.
        • Colditz G.A.
        Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.
        Prev. Med. 1991; 20: 47-63
        • Grady D.
        • Rubin S.M.
        • Petitti D.B.
        • Fox C.S.
        • Black D.
        • Ettinger B.
        • Ernster V.L.
        • Cummings S.R.
        Hormone therapy to prevent disease and prolong life in postmenopausal women.
        Ann. Intern. Med. 1992; 117: 1016-1037
        • Col N.F.
        • Eckman M.H.
        • Karas R.H.
        • Pauker S.G.
        • Goldberg R.J.
        • Ross E.M.
        • Orr R.K.
        • Wong J.B.
        Patient-specific decisions about hormone replacement therapy in postmenopausal women.
        JAMA. 1997; 277: 1140-1147
        • Stampfer M.J.
        • Willett W.C.
        • Colditz G.A.
        • Rosner B.
        • Speizer F.E.
        • Hennikens C.H.
        A prospective study of postmenopausal estrogen therapy and coronary heart disease.
        N. Engl. J. Med. 1985; 313: 1044-1049
        • Avila M.H.
        • Walker A.M.
        • Jick H.
        Use of replacement estrogens and the risk of myocardial infarction.
        Epidemiology. 1990; 1: 128-133
      3. American College of Physicians. Guidelines for counselling postenopausal women about preventive hormone therapy. Am Intern Med 1992;117:1038–41.

      4. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopusal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program. Boston University Medical Center. N Engl J Med 1974;290:15–9.

      5. Collaborative Group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy; collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047–59.

        • Hulley S.
        • Grady D.
        • Bush T.
        • Furberg C.
        • Herrington D.
        • Riggs B.
        • Vittinghoff E.
        Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.
        JAMA. 1998; 380: 605-613
        • Herrington D.M.
        • Reboussin D.M.
        • Brosnihan K.B.
        • Sharp P.C.
        • Shumaker S.A.
        • Snyder T.E.
        • Furberg C.D.
        • Kowalchuk G.J.
        • Stuckey T.D.
        • Rogers W.J.
        • Givens D.H.
        • Waters D.
        Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.
        N. Engl. J. Med. 2000; 343: 522-529
        • Clarkson T.B.
        • Anthony M.S.
        • Morgan T.M.
        Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens.
        J. Clin. Endocrinol. Metab. 2001; 86: 41-47
        • Kritharides L.
        • Teede H.J.
        What role can diet play in the increased risk of cardiovascular disease in women aged 40 years and over?.
        Med. J. Aust. 2000; 173: S101-S102
        • Sirtori C.R.
        • Lovati M.R.
        Soy proteins and cardiovascular disease.
        Curr. Atheroscler. Rep. 2001; 3: 47-53
      6. Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: importance of the chemical composition of soybean products.

        • Glazier M.G.
        • Bowman M.A.
        A review of the evidence for the use of phytoetrogens as a replacement for traditional estrogen replacement therapy.
        Arch. Intern. Med. 2001; 161: 1161-1172
        • Nestel P.J.
        • Yamashita T.
        • Sasahara T.
        • Chin-Dusting J.P.F.
        • Esler M.D.
        • Dart A.M.
        • Jennings G.L.
        Soy isoflavone improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women.
        Arteriosler. Thromb. Vasc. Biol. 1997; 17: 3392-3398
        • Greaves K.A.
        • Parks J.S.
        • Williams J.K.
        • Wagner J.D.
        Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein improves plasma lipids in ovariectomized cynomolgus monkeys.
        J. Nutr. 1999; 129: 1585-1592
        • Umland E.M.
        • Cauffield J.S.
        • Kirk J.K.
        • Thomason T.E.
        Phytoestrogens as therapeutic alternatives to traditional hormone replacement in postmenopausal women.
        Pharmacotherapy. 2000; 20: 981-990
        • Berrino F
        • Bellati C
        • Secreto G
        • Camerini E
        • Pala V
        • Panico S
        • Allegro G
        • Kaaks R.
        Reducing bioavaible sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomised trial.
        Cancer Epidemiol Biomarkers Prev. 2001; 10: 25-33
        • Moerman C.J.
        • van Hout B.A.
        • Bonneux L.
        • Witteman J.C.
        Postmenopausal hormone therapy: less favourable risk-benefit ratios in healthy Dutch women.
        J. Intern. Med. 2000; 248: 143-150
        • Simon J.A.
        • Hsia J.
        • Cauley J.A.
        • Richards C.
        • Harris F.
        • Fong J.
        • Barrett-Connor E.
        • Hulley S.B.
        Postmenopausal hormone therapy and risk of stroke: the heart and Estrogen-progestin Replacement Study (HERS).
        Circulation. 2001; 103: 638-642
        • Anderson J.W.
        • Johnstone B.M.
        • Cook-Newell M.E.
        Meta-analysis of the effects of soy protein intake on serum lipids.
        N. Engl. J. Med. 1995; 333: 276-282
      7. The role of Isoflavones in menopausal health: consensus opinion of the North American Menopause Society. (without authors) Menoapause 2000;7(4):215–229.

        • Goodman M.T.
        • Wilkens L.R.
        • Hankin J.H.
        • Lyu L.C.
        • Wu A.H.
        • Kolonel L.N.
        Association of soy and fiber consumption with the risk of endometrial cancer.
        Am. J. Epidemiol. 1997; 146: 294-306